Shareholder

Microbix Announces Annual and Special Meeting Voting Results

Retrieved on: 
Monday, April 1, 2024
Special, Shareholder, Annual, Circular, OTCQB, TSX

MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the Company”), a life sciences innovator and exporter, announces the voting results from the Annual and Special Meeting of Shareholders of the Company (the “Meeting”) which was held on March 27, 2024.

Key Points: 
  • MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the Company”), a life sciences innovator and exporter, announces the voting results from the Annual and Special Meeting of Shareholders of the Company (the “Meeting”) which was held on March 27, 2024.
  • At the Meeting, 42.64% of the issued and outstanding shares were represented.
  • Shareholders voted in favour of all resolutions brought before the Meeting.
  • All of the board of directors nominees listed in the Circular were re-elected as directors of Microbix.

ArcelorMittal publishes convening notice for its Annual General Meeting of shareholders

Retrieved on: 
Friday, March 29, 2024
Annual, Documentation, Form, AGM, Equity, Shareholder, Annual report, Security (finance)

ArcelorMittal (the ‘Company’) announces the publication of the convening notice for its Annual General Meeting of shareholders (the ‘General Meeting’), which will be held on 30 April 2024 at 3 p.m. CET at the Company’s registered office, 24-26, boulevard d’Avranches, L-1160 Luxembourg, Grand-Duchy of Luxembourg.

Key Points: 
  • ArcelorMittal (the ‘Company’) announces the publication of the convening notice for its Annual General Meeting of shareholders (the ‘General Meeting’), which will be held on 30 April 2024 at 3 p.m. CET at the Company’s registered office, 24-26, boulevard d’Avranches, L-1160 Luxembourg, Grand-Duchy of Luxembourg.
  • The convening notice, the Annual Report 2023, the Form 20-F 2023, the voting forms and all other meeting documentation will be available on ArcelorMittal's website www.arcelormittal.com under Investors – Equity investors – Shareholders events – AGM – Annual General Meeting of shareholders, 30 April 2024.
  • The Company also announces that as of 28 March 2024 Mrs. Karyn Ovelmen has stepped down from her position as chair of the Board’s Audit & Risk Committee.
  • The new chair of the Company’s Audit & Risk Committee will be appointed at the next Board of Directors meeting and Mrs. Ovelmen will hold the position on a caretaker basis until 30 April 2024.

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, March 28, 2024
CARE, Sleep apnea, CPAP, Continuous positive airway pressure, Exercise, Environment, VIP, Obstructive sleep apnea, PAP, Shareholder, Webcast, Patient, DME, Sleep, DNA, ODO, AHI, Messenger, Myotherapy, Security (finance), Danaher Corporation, Clinical trial, Therapy, Annual report, Optimism, Dentist, FDA, Food, Pharmaceutical industry

LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults)), today reported financial results and operating highlights for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Importantly, Vivos believes that governmental investigations of unrelated third parties with non-FDA approved products in the sleep apnea treatment space adversely impacted new Vivos case starts and VIP enrollments during 2023.
  • Vivos’ CARE appliances include the flagship DNA oral appliance, the mRNA oral appliance and the mmRNA oral appliance.
  • Since then, we’ve received high levels of inquiries related to our Vivos CARE products that treat OSA in adults.
  • A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations .

Gabelli Dividend & Income Trust Nominates Media and Communications Veteran Robert P. Astorino for Election to Board of Trustees

Retrieved on: 
Thursday, March 28, 2024
Fordham University, Trustee, Westchester County, New York, Public policy, Westchester County Executive, GDV, Local government, Radio, Shareholder, Fund, Sirius XM

Mr. Astorino has extensive experience in media and communications.

Key Points: 
  • Mr. Astorino has extensive experience in media and communications.
  • He currently is President of SR Media LLC, a company that advises CEOs and other leaders on public policy, media, and government relations.
  • He held senior management positions at Disney’s ESPN Radio, SiriusXM, and the Catholic Archdiocese of New York.
  • In these roles, he oversaw the development of key divisions, directly managing personnel, budgets, and operations.

Tritium Confirms Effective Date of Reverse Stock Split

Retrieved on: 
Thursday, March 28, 2024
Shareholder, Mass meeting, Consolidation

BRISBANE, Australia, March 28, 2024 (GLOBE NEWSWIRE) -- Tritium DCFC Limited (Nasdaq: DCFC) (“Tritium” or the “Company”), a global developer and manufacturer of direct current (“DC”) fast chargers for electric vehicles (“EVs”), today confirms the effective date of its reverse stock split.

Key Points: 
  • BRISBANE, Australia, March 28, 2024 (GLOBE NEWSWIRE) -- Tritium DCFC Limited (Nasdaq: DCFC) (“Tritium” or the “Company”), a global developer and manufacturer of direct current (“DC”) fast chargers for electric vehicles (“EVs”), today confirms the effective date of its reverse stock split.
  • As previously reported, on March 22, 2024, the Company held an Extraordinary General Meeting of Shareholders to consider the resolution to consolidate Company ordinary shares (the “Shares”) on the basis that every two-hundred (200) Shares be consolidated into one (1) Share (the “Consolidation”).
  • Following the completion of listing exchange procedures, the effective date of the Consolidation will be April 2, 2024.

Sword Group: Availability of preparatory documents for the Ordinary General Meeting of 29 April 2024

Retrieved on: 
Thursday, March 28, 2024
Single Form, Proxy, Shareholder, Annual, RESA, Mass meeting, Luxemburger Wort

The Ordinary General Meeting of Shareholders of Sword Group SE will be held at 11 a.m. on 29 April 2024.

Key Points: 
  • The Ordinary General Meeting of Shareholders of Sword Group SE will be held at 11 a.m. on 29 April 2024.
  • The notice of meeting including the agenda was published in the RESA (Recueil électronique des sociétés et associations) and in the Luxemburger Wort on 28 March 2024.
  • The terms and conditions for attending and voting at this meeting are set out in this notice.
  • Pending approval at the Annual General Meeting on April 29.

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Research, NCI, AON, Development, Sarcoma, Disease, Neuroblastoma, Shareholder, Patient, CNS, Fast Track, Cash, SBIR, NDA, Syndrome, Cancer, MRR, CLR, BNS, University, Head, External beam radiotherapy, Cure, Wisconsin Alumni Research Foundation, WAM, HERE, Completeness, Safety, Tat, Intellectual property, Patent, PLE, WARF, Symantec Endpoint Protection, Tranche, UW, Pharmaceutical industry

FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.
  • Net cash used in operating activities during the twelve months ended December 31, 2023, was approximately $32.4 million.
  • General and Administrative Expense: G&A expense for the year ended December 31, 2023, was $10.7 million, compared to $9.6 million for the year ended December 31, 2022.
  • Cellectar management will host a conference call for investors today, March 14, 2024, beginning at 8:30 am Eastern Time to discuss these results and answer questions.

Orion Group Holdings, Inc. Announces Retirement of Board Member

Retrieved on: 
Monday, March 25, 2024
Shareholder, Growth, Lead, Management

Effective upon Mr. Daerr’s retirement, the Board has determined to reduce its size from eight directors to seven directors, six of whom are independent.

Key Points: 
  • Effective upon Mr. Daerr’s retirement, the Board has determined to reduce its size from eight directors to seven directors, six of whom are independent.
  • Austin Shanfelter, Orion’s Chairman of the Board, commented, “We want to thank Richard for his years of service to the Company and his many valuable contributions, including his board leadership in the transition of Orion to a public company, establishing the standards for governance, the growth of the Company, and agreeing to serve as our Lead Independent Director through our recent executive transition.
  • We wish him all the best in his future endeavors.”
    Mr. Daerr stated, “It has been my distinct honor to serve on this Board for almost seventeen years and lead the Board for almost all of that time.
  • I am proud of the tremendous transformation the Company has achieved over this time, and I leave with great confidence in Orion’s future and the strength of its Board.”

Perion Network Announces Filing of Annual Report on Form 20-F for Fiscal Year 2023

Retrieved on: 
Monday, April 8, 2024
Advertising, Communications, Digital Marketing, Technology, Software, Networks, Shareholder, Bank statement, Annual report, Security (finance), Cryptocurrency

Perion Network Ltd. (NASDAQ & TASE: PERI ), a technology leader in connecting advertisers to consumers across all major digital channels, announced today the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (SEC).

Key Points: 
  • Perion Network Ltd. (NASDAQ & TASE: PERI ), a technology leader in connecting advertisers to consumers across all major digital channels, announced today the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (SEC).
  • The annual report, containing audited consolidated financial statements for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on April 8, 2024, is now accessible on our website at https://www.perion.com/ .
  • In addition to online availability, Shareholders and interested parties may receive a hard copy of the report at no additional cost.
  • To request a hard copy of the annual report, shareholders are welcome to contact Perion Network Ltd. through the details provided on our website.

Notice of Annual General Meeting (AGM) of Bioretec Ltd

Retrieved on: 
Friday, April 5, 2024
Remuneration, Charter, Annual, EUR, Chair, PwC, Nomination, Exercise, Communication, Address, Travel, Mass meeting, Shareholder, Bank statement, Investment company, Annual general meeting, Tax, Companies Act, Chapter Five, Privacy, EET, Holding company

TAMPERE, Finland, April 5, 2024 /PRNewswire/ -- The shareholders of Bioretec Ltd are hereby invited to the Annual General Meeting to be held on 26 April 2024 at 10:00 a.m. (Finnish time) at Bioretec premises in the auditorium of Tampark, at the address Yrittäjänkulma 5, FI-33710 Tampere, Finland.

Key Points: 
  • A shareholder may participate in the Annual General Meeting and exercise their rights at the meeting by way of proxy representation.
  • The authorization is valid until the end of the next Annual General Meeting, however, no longer than until 30 June 2025.
  • The Board of Directors proposes that the Annual General Meeting resolve to establish a shareholders' nomination board ("Nomination Board"), responsible for annually preparing and presenting to the Annual General Meeting and, if necessary, to an Extraordinary General Meeting, proposals on the composition (number of the members of the Board of Directors and the nominees) and remuneration of the Board of Directors.
  • The meeting minutes of the Annual General Meeting will be available on the company's website no later than 10 May 2024.